fbpx

Parkinsons Institute and Clinical Center and Axial Biotherapeutics Announce Collaboration to Target Gastrointestinal Metabolites That May Contribute to Parkinsons Disease

Parkinson’s Institute and Clinical Center (PICC) and Axial
Biotherapeutics announced today a collaboration to investigate
interventions targeting gastrointestinal (GI) metabolites that may cause
Parkinson’s Disease (PD). The interventions, to be developed and
identified by Axial, will build on the work of Axial’s scientific
Co-founder and Caltech Professor, Sarkis Mazmanian, Ph.D. Axial’s unique
approach to PD interventions is inspired by the effects the microbiome
and its metabolites have on PD progression.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180618005280/en/

As part of the collaboration, Axial and the PICC have formed a joint
preclinical research collaboration, studying Axial’s microbiome-inspired
interventions in the PICC’s unique cellular and animal models for PD and
its effects over the GI system.

“Our team is conducting advanced clinical research, which suggests that
disorders like Parkinson’s are not just a brain condition but very
likely have origins in the GI system,” said Carrolee Barlow, M.D.,
Ph.D., Chief Executive Officer, Parkinson’s Institute and Clinical
Center. “We are excited to join forces with Axial Biotherapeutics and
their team to investigate an intervention with the potential to
eradicate and block these microbial effects and improve GI function. It
is our ultimate goal to determine if this approach can stop PD from
progressing. Partnerships like this, along with financial donations,
will make our goal of finding a solution for PD a reality.”

In parallel to the newly formed collaboration, Dr. Barlow has joined
Axial’s recently formed Neurology
Scientific and Clinical Advisory Board, and will help guide the
Company’s clinical programs.

“The collaboration with Dr. Barlow and her team at the PICC is expected
to significantly increase the pace of development for our approach to
PD,” added David H. Donabedian, PhD, Co-founder and CEO of Axial
Biotherapeutics. “We truly appreciate the enthusiasm and collaborative
spirit exhibited by Dr. Barlow and her team, and we look forward to
seeing the fruits of this partnership, which will hopefully bring us
several steps closer to finding a better solution for this disease.”

About Axial’s Parkinson’s research program

Studies performed by Axial’s scientific Co-founder and Caltech
Professor, Sarkis Mazmanian, Ph.D. and others, have shown that human gut
bacteria can potentiate numerous PD-like features in a robust mouse
model of the disease, and suggested that alterations in the human
microbiome may be a novel and causal risk factor for PD. In mice
overexpressing human ?-Synuclein (?-Syn), intestinal microbiota were
required to induce GI and motor deficits, and ?-Syn pathology in the
brain. Furthermore, antibiotic treatment ameliorated pathophysiology in
adult animals, while microbial colonization promoted it, suggesting
disease potentially arises from signaling between the gut and the brain.
Finally, colonization of ?-Syn overexpressing mice with microbiota from
PD patients enhanced physical impairments compared to microbiota
transplants from healthy human donors. These findings powered Axial’s
search for solutions that will improve PD by affecting the microbiome
and its metabolites.

About the Parkinson’s Institute and Clinical
Center:

The Parkinson’s Institute and Clinical Center is at the forefront of
patient care and therapy development. We are the nation’s only Institute
that provides patient care, basic science research, and clinical
research in one integrated model. Our unique freestanding organization
directly connects research to patient care – from the “lab bench to
bedside.” For 30 years, our team of epidemiologists, physicians,
scientists, and therapists, have been at the forefront of every clinical
and scientific discovery in the field of Parkinson’s research.

Since our inception, patients have come from 38 states and many foreign
countries for their care. We have managed more than 135 clinical
research trials, medically evaluating more than 95 different drugs and
therapies for Parkinson’s. The result: our Institute has been directly
involved in bringing every Parkinson’s drug currently available to the
market. The Institute is at the forefront of discovering and developing
the latest, most innovative treatments and therapies for people living
with Parkinson’s.

For more information visit www.thepi.org
or call (408) 734-2800.

About Axial Biotherapeutics:

Axial Biotherapeutics is a leading biopharmaceutical company harnessing
the link between the human gut microbiome and the central nervous system
to develop a new class of biotherapeutics to improve the quality of life
for people with neurological diseases and disorders. www.axialbiotherapeutics.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20180618005280/en/